ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0871

Clinical Significance of Plasma Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Levels to Assess the Cardiovascular Risk in Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Lee, Yu ho, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
  • Lee, So-young, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
  • Jeong, Hyeyun, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
  • Kim, Yang gyun, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of)
  • Moon, Ju young, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of)
  • Lee, Sangho, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of)
  • Kim, Jin sug, Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Jeong, Kyung hwan, Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Ahn, Shin-Young, Korea University, Seongbuk-gu, Seoul, Korea (the Republic of)
  • Lee, Dong-Young, Seoul Veterans Hospital, Gangdong-gu, Seoul, Korea (the Republic of)
  • Hwang, Hyeon Seok, Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
Background

Matrix metalloproteinases (MMPs) are endopeptidases that control extracellular matrix synthesis and degradation. Two MMP subtypes, MMP-2 and MMP-9, are known to play important roles in the development and progression of cardiovascular (CV) disease, but its clinical relevance as predictors of cardiovascular events is unclear in hemodialysis patients.

Methods

We prospectively enrolled 435 patients undergoing maintenance hemodialysis from K-cohort between June 2016 and April 2019. Plasma MMP-2, MMP-9 levels, and several biomarkers were measured at the time of study data entry. Primary endpoint was defined as a composite of cardiovascular events.

Results

Plasma MMP-2 level were increased in patients with incident CV events than those without CV events, whereas plasma MMP-9 levels were not different between groups. MMP-2 levels were positively correlated with circulating cardiac markers including brain natriuretic peptides (BNP), N-terminal proBNP, and heart-type fatty acid binding protein. The cumulative event rate of the composite of CV events was significantly greater in patients with higher MMP-2 tertile 3 than in those with other MMP-2 tertile 1 (p = 0.015). MMP-2 tertile 3 was associated with a 2.77-fold higher risk of the composite of CV events (95% CI, 1.40–5.45) and 4.67-fold higher risk of cardiac events (95% CI, 2.06–10.56) after multivariable adjustments. However, plasma MMP-9 levels were not positively correlated with circulating cardiac markers, and not associated with risk of incident CV events.

Conclusion

Higher plasma MMP-2 levels, but not MMP-9 levels, had the positive relationship with circulating levels of cardiac pathology markers, and were associated with increased risks of incident CV events and cardiac events among hemodialysis patients.